Levetiracetam

Abstract

Calcium carbonate and aluminum hydroxide do not affect the pharmacokinetics of levetiracetam [1].

This is a preview of subscription content, log in via an institution to check access.

Tax calculation will be finalised at checkout

Purchases are for personal use only

Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–24.
Article PubMed CAS Google Scholar
Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 2001;46:93–9.
Article PubMed CAS Google Scholar
Mink S, Muroi C, Bjeljac M, Keller E. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurismal subarachnoid haemorrhage. Clin Neurol Neurosurg. 2011;113:644–8.
Article PubMed CAS Google Scholar
Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85(2):77–85.
Article PubMed CAS Google Scholar
Sabers A, Christensen J. No effect of oral contraceptives on the metabolism of levetiracetam. Epilepsy Res. 2011;95:277–9.
Article PubMed CAS Google Scholar
Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47:55–63.
Article PubMed CAS Google Scholar

UCL-Institute of Neurology Department of Clinical and Experimental Epilepsy, Queen Square, London, London
P. N. Patsalos
Epilepsy Society Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire, UK
P. N. Patsalos

Authors

P. N. Patsalos
View author publications
You can also search for this author in PubMed Google Scholar

Patsalos, P.N. (2013). Levetiracetam. In: Antiepileptic Drug Interactions. Springer, London. https://doi.org/10.1007/978-1-4471-2434-4_38